

Dictionary of NCCR SEER*Stat Variables
December 2023 Submission

| December 2023 Submission of NCCR Data in SEER*Stat | | | |
|--|---|--|---------------------|
| | Item # refers to the NAACCR item number - see https://apps.naaccr.org/data-dictionary/data-dictionary/version=23/chapter-view/ | | |
| | CS= Collaborative Staging | | |
| Name | NAACCR Item # | Description | Category name |
| Age recode with single ages and 85+ | | Patient's age at diagnosis with all ages over 85 grouped together. In rate sessions this is the population age variable. | Age at Diagnosis |
| Sex | 220 | Includes 1= Male and 2=Female from Sex [NAACCR Item #220] plus a total of male and female. This is used to link to the correct populations for males and females when calculating sex-specific rates. | Race, Sex, Year Dx |
| Year of Diagnosis PRCDA 2020 | 390 | From NAACCR Name=Date of Diagnosis, Item #=390 | Race, Sex, Year Dx |
| | | This data item identifies whether or not the county of diagnosis is served by PRCDA. The primary use of this field is to be able to limit analyses of AI/AN race to areas served by PRCDA. See https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity OR https://seer.cancer.gov/seerstat/variables/countyattribs/ | Race, Sex, Year Dx |
| Race Recode (W, B, AIAN, API) | | Caution should be exercised when using this variable. For more information, see https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/ . | Race, Sex, Year Dx |
| Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic) | | Caution should be exercised when using this variable. For more information, see https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/ . | Race, Sex, Year Dx |
| ICCC site recode 3rd edition/IARC 2017 | | A site/histology recode that is mainly used to analyze data on children. The recode was applied to all cases no matter the age in order that age comparisons can be made with these groupings. Based on ICD-O-3. Note that cases diagnosed before 2001 were not coded under ICD-O-3 and were converted to ICD-O-3 and may not have the specificity of cases after 2000 that were coded directly under ICD-O-3. For more information on this International Classification of Childhood Cancer (ICCC) site recode, see https://seer.cancer.gov/iccc | Site and Morphology |
| ICCC site recode extended 3rd edition/IARC 2017 | | Based on ICD-O-3. For more information on this International Classification of Childhood Cancer (ICCC) site/histology recode, see https://seer.cancer.gov/iccc . While the recode is normally used for childhood cancers, it is on the file for all ages so that childhood cancers could be compared across age groups. For more information, see https://seer.cancer.gov/iccc/iccc-iarc-2017.html | Site and Morphology |
| AYA site recode 2020 Revision | | A site/histology recode that is mainly used to analyze data on adolescent and young adults. The recode was applied to all cases no matter the age in order that age comparisons can be made with these groupings. For more information, see https://seer.cancer.gov/ayarecode/ | Site and Morphology |

Dictionary of NCCR SEER*Stat Variables
December 2023 Submission

| Name | NAACCR Item # | Description | Category name |
|--|---------------|---|---------------------|
| Primary site - labeled | 400 | This provides the primary site code in ICD-O-3 and a descriptive primary site label. Note that the label is the preferred ICD-O-3 bolded name and there may be other sites or sub-sites included in the code but not reflected in the preferred term. Refer to ICD-O-3 for further information. | Site and Morphology |
| Primary Site | 400 | Codes are found in the Topography section of the International Classification of Diseases for Oncology (ICD-O) 3rd edition. | Site and Morphology |
| Histologic type ICD-O-3 | 522 | Based on histology codes in ICD-O-3. Cases diagnosed before 2001 were coded in earlier versions and converted to ICD-O-3 and coded directly for 2001+. | Site and Morphology |
| Behavior code ICD-O-3 | | Based on behavior codes in ICD-O-3. Behavior code has had the same definitions in previous versions but may be associated differently with histologies over time. For example, borderline of the ovary were considered malignant in ICD-O-2 but benign in ICD-O-3. Cases diagnosed before 2001 were coded in earlier versions and converted to ICD-O-3 and coded directly for 2001+. In situ bladder cases have been converted to malignant in this field. See Behavior recode for consistency over time. | Site and Morphology |
| Lymphoid neoplasm recode 2021 Revision | | A site/histology recode that is mainly used to analyze data on lymphoma sub-types. Based on ICD-O-3. Note that cases diagnosed before 2001 were not coded under ICD-O-3 and were converted to ICD-O-3 and may not have the specificity of cases after 2000 that were coded directly under ICD-O-3. For more information, see https://seer.cancer.gov/lymphomarecode/ | Site and Morphology |
| Grade (thru 2017) | 440 | From NAACCR Name=Grade, Item #=440 | Site and Morphology |
| Grade Clinical (2018+) | 3843 | Refer to the most recent version of the NAACCR SSDI Manual for additional site-specific instructions. | Site and Morphology |
| Grade Pathological (2018+) | 3844 | Refer to the most recent version of the NAACCR SSDI Manual for additional site-specific instructions. | Site and Morphology |
| Diagnostic confirmation | 490 | From NAACCR Name=Diagnostic Confirmation, Item #=490 | Site and Morphology |
| ICD-O-3 Hist/behavior, labeled | | Labeled version of ICD-O-3 Histology/Behavior values for all behaviors. See SEER*Stat dictionary for labels. | Site and Morphology |
| ICD-O-3 Hist/behavior, malig, labeled | | Labeled version of ICD-O-3 Histology Behavior values for malignant tumors. All non-malignant tumors are grouped into one value. See SEER*Stat dictionary for labels. | Site and Morphology |
| Schema ID (2018+) | 3800 | This variable allows the linkage of 2018+ Site-Specific Data Items (SSDIs), including grade data items, with the appropriate site/histology grouping. | Site and Morphology |
| Laterality | 410 | From NAACCR Name=Laterality, Item #=410 | Site and Morphology |

Dictionary of NCCR SEER*Stat Variables
December 2023 Submission

| Name | NAACCR Item # | Description | Category name |
|---|---------------|--|------------------------------------|
| Behavior recode for analysis | | This recode was created so that data analyses could eliminate major groups of histologies/behaviors that weren't collected consistently over time, for example benign brain, myelodysplastic syndromes, and borderline tumors of the ovary. Created from ICD-O-3 behavior and histology. For more information, see https://seer.cancer.gov/behavrecode | Site and Morphology |
| Site recode ICD-O-3/WHO 2008 | | A recode based on Primary Site and Histology in order to make analyses of site/histology groups easier. For example, the lymphomas are excluded from stomach and Kaposi and mesothelioma are separate categories based on histology. For more information, see https://seer.cancer.gov/siterecode/icdo3_dwhoheme/ | Site and Morphology |
| Summary Stage (2004+) | | Combined Summary Stage field to facilitate stage analyses over time. Created from Summary Stage 2000 (2004-2017) & Derived Summary Stage 2018 (2018+). Due to inconsistency of details for regional stage between the 2 fields, all regional codes collapsed into into one category. | Stage - LRD (Summary and Historic) |
| SEER summary stage 2000 (2001-2003) | | SEER Summary Stage 2000 for years 2001-2003. | Stage - LRD (Summary and Historic) |
| SEER Summary stage 1977 (1995-2000) | | SEER Summary Stage 1997 for years 1995-2000. | Stage - LRD (Summary and Historic) |
| Fibrosis Score (2018+) | 3835 | NAACCR Name=Fibrosis Score, Item #=3835. | Site-Specific Data Items |
| Brain Molecular Markers (2018+) | 3816 | NAACCR Name=Brain Molecular Markers, Item #=3816. | Site-Specific Data Items |
| Breslow Tumor Thickness (2018+) | 3817 | NAACCR Name=Breslow Tumor Thickness, Item #=3817. | Site-Specific Data Items |
| LDH Pretreatment Lab Value (2018+) | 3932 | NAACCR Name=LDH Lab Value, Item #=3932. | Site-Specific Data Items |
| PSA Lab Value Recode (2010+) | | Coded for cases coded as Prostate in BOTH TNM 7/CS v0204+ Schema Recode & EOD Schema Id Recode. Created from NAACCR Item #3920 & CS site-specific factor 1 (NAACCR #2880). Measurement in nanograms/milliliter (ng/ml). For more information, see https://seer.cancer.gov/seerstat/variables/seer/ssdi/ | Site-Specific Data Items |
| RX summ--surg prim site (2003+) | 1290 | NAACCR Name=RX Summ--Surg Prim Site, Item #=1290. The information in this field is site-specific. The amount/detail of information has varied over time and caution should be used when looking at trends over time. For site-specific codes, see Appendix C of https://seer.cancer.gov/tools/codingmanuals/ | Therapy |
| RX summ--surg oth reg/dis (2003+) | 1294 | From NAACCR Name=RX Summ--Surg Oth Reg/Dis, Item #=1294 | Therapy |
| RX summ--surg/rad seq (2010+) | 1380 | From NAACCR Name=RX Summ--Surg/Rad Seq, Item #=1380 | Therapy |
| Reason for no CA dir surg (2006+) | 1340 | From NAACCR Name=Reason for No Surgery, Item #=1340 | Therapy |
| RX Summ--Systemic Surg Seq (2010+) | 1639 | From NAACCR Name=RX Summ--Systemic/Sur Seq, Item #=1639 | Therapy |
| Radiation recode (2003+) | | Created from radiation and Phase 1 (and 2/3 when available) modalities and reason no radiation. | Therapy |
| Chemotherapy recode (yes, no/unk) (2010+) | | Created from RX Summ--Chemo, Item #=1390 | Therapy |
| RX Summ--Scope Reg LN Sur (2003+) | 1292 | NAACCR Name=RX Summ--Scope Reg LN Sur, Item #=1292. Changed to Unknown or not applicable for breast cancer cases. | Therapy |

Dictionary of NCCR SEER*Stat Variables
December 2023 Submission

| Name | NAACCR Item # | Description | Category name |
|---|---------------|---|------------------------------------|
| CS tumor size (2004-2015) | 2800 | From NAACCR Name=CS Tumor Size, Item #=2800 | Extent of Disease |
| CS extension (2004-2015) | 2810 | From NAACCR Name=CS Extension, Item #=2810 | Extent of Disease |
| CS lymph nodes (2004-2015) | 2830 | From NAACCR Name=CS Lymph Nodes, Item #=2830 | Extent of Disease |
| CS mets at dx (2004-2015) | 2850 | From NAACCR Name=CS Mets at DXs, Item #=2850 | Extent of Disease |
| Regional nodes examined (1998+) | 830 | From NAACCR Name=Regional Nodes Examined, Item #=830 | Extent of Disease |
| Regional nodes positive (1998+) | 820 | From NAACCR Name=Regional Nodes Positive, Item #=820 | Extent of Disease |
| Tumor Size Summary (2016+) | 756 | From NAACCR Name=Tumor Size Summary, Item #=756 | Extent of Disease |
| Derived HER2 Recode (2010+) | | Created with combined information from several CS site-specific factors (2010-2017) and HER2 Overall Summary (2018+) (NAACCR Item #=3855). For more information, see https://seer.cancer.gov/seerstat/databases/ssf/her2-derived.html . Coded for cases coded as Breast in TNM 7/CS v0204+ Schema AND EOD Schema Id. | Extent of Disease |
| ER Status Recode Breast Cancer (2010+) | | Created with combined information from CS site-specific factor 1 (2010-2017) (NAACCR Item #=2880) and Estrogen Receptor Summary (2018+) (NAACCR Item #=3827). Coded for cases coded as Breast in TNM 7/CS v0204+ Schema AND EOD Schema Id AND Site recode ICD-O-3/WHO 2008. | Extent of Disease |
| PR Status Recode Breast Cancer (2010+) | | Created with combined information from CS site-specific factor 2 (2010-2017) (NAACCR Item #=2890) and Progesterone Receptor Summary (2018+) (NAACCR Item #=3915). Coded for cases coded as Breast in TNM 7/CS v0204+ Schema AND EOD Schema Id AND Site recode ICD-O-3/WHO 2008. | Extent of Disease |
| Lymph-vascular Invasion (2018+ varying by schema) | 1182 | Available only for testis and penis because it is needed for AJCC 6th & 7th ed staging. | Extent of Disease |
| Survival months - blended | 1784 | NAACCR Item #=1784, created using complete dates, including days, therefore may differ from survival time calculated from year and month only. Blended means that the Active Followup fields are used for some registries and Presumed Alive Followup fields are used for others. For more information, see https://seer.cancer.gov/survivaltime . | Cause of Death (COD) and Follow-up |
| Survival months flag - blended | 1783 | NAACCR Item #=1783, created using complete dates, including days, therefore may differ from survival time calculated from year and month only. Blended means that the Active Followup fields are used for some registries and Presumed Alive Followup fields are used for others. For more information, see https://seer.cancer.gov/survivaltime . | Cause of Death (COD) and Follow-up |
| Vital status recode | 1762 | Any patient that dies after the follow-up cut-off date is recoded to alive as of the cut-off date. | Cause of Death (COD) and Follow-up |
| Record number recode | 1775 | Sequentially numbers a person's tumors within each submission. Order is based on date of diagnosis and then sequence #. | Multiple Primary Fields |
| Sequence number--central | 380 | NAACCR Name=Sequence Number--Central, Item #=380 | Multiple Primary Fields |

Dictionary of NCCR SEER*Stat Variables
December 2023 Submission

| Name | NAACCR Item # | Description | Category name |
|-------------------------------------|---------------|---|-------------------------------|
| Age recode <1 year olds | | The age recode variable is based on Age at Diagnosis (single-year ages). This recode has 19 age groups in the age recode variable (< 1 year, 1-4 years, 5-9 years, ..., 85+ years). | Race and Age (case data only) |
| Yost Quintile (US) | 9610 | For more information, refer to the "SES Quintiles" section of https://seer.cancer.gov/seerstat/databases/census-tract/index.html | Tract Derived |
| Month of diagnosis recode | 1788 | NAACCR Item #=1788, month of diagnosis from survival months field creation | Dates |
| Year of last contact recode blended | 1782 | The earlier of the Year of Last Contact (NAACCR #1750) and the study cutoff. Blended means that the Active Followup fields are used for some registries and Presumed Alive Followup fields are used for others. Coded survival for some registries and presumed alive for others. | Dates |
| CoC Accredited Flag (2018+) | 2152 | CoC Accredited Flag is assigned at the point and time of data abstraction to label an abstract being prepared for an analytic cancer case at a facility accredited by the Commission on Cancer (CoC). The flag may be assigned manually or can be defaulted by the registry's software. | Other |
| Type of Reporting Source | 500 | Contains information on where the information from this case came. Is used in survival analysis to eliminate cases which are found at autopsy or the only information is from a death certificate. | Other |